Compare Stocks: NERV, HELP, ACHV, and PHAT

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACHV Achieve Life Sciences	$7.99	$6.35	$2.62 ▼ $8.61	$822.17M	2.24	1.35 million shs	1.06 million shs
HELP Cybin	$12.59	$7.82	$3.76 ▼ $12.95	$919.83M	0.55	1.80 million shs	2.16 million shs
NERV Minerva Neurosciences	$4.84	$4.46	$1.93 ▼ $12.46	$231.11M	-0.1	246,967 shs	106,449 shs
PHAT Phathom Pharmaceuticals	$8.87	$10.38	$8.21 ▼ $18.31	$717.58M	0.51	1.78 million shs	979,184 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACHV Achieve Life Sciences	0.00%	+5.27%	+30.98%	+70.36%	+173.63%
HELP Cybin	0.00%	+5.00%	+65.22%	+169.02%	+1,258,999,900.00%
NERV Minerva Neurosciences	0.00%	+5.68%	+19.80%	-7.98%	+99.18%
PHAT Phathom Pharmaceuticals	0.00%	-7.41%	-22.47%	-21.71%	-25.52%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACHV Achieve Life Sciences	$7.99	$6.35	$2.62 ▼ $8.61	$822.17M	2.24	1.35 million shs	1.06 million shs
HELP Cybin	$12.59	$7.82	$3.76 ▼ $12.95	$919.83M	0.55	1.80 million shs	2.16 million shs
NERV Minerva Neurosciences	$4.84	$4.46	$1.93 ▼ $12.46	$231.11M	-0.1	246,967 shs	106,449 shs
PHAT Phathom Pharmaceuticals	$8.87	$10.38	$8.21 ▼ $18.31	$717.58M	0.51	1.78 million shs	979,184 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACHV Achieve Life Sciences	0.00%	+5.27%	+30.98%	+70.36%	+173.63%
HELP Cybin	0.00%	+5.00%	+65.22%	+169.02%	+1,258,999,900.00%
NERV Minerva Neurosciences	0.00%	+5.68%	+19.80%	-7.98%	+99.18%
PHAT Phathom Pharmaceuticals	0.00%	-7.41%	-22.47%	-21.71%	-25.52%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACHV Achieve Life Sciences	3.00	Buy	$15.00	87.73% Upside
HELP Cybin	3.00	Buy	$48.60	286.02% Upside
NERV Minerva Neurosciences	1.75	Reduce	$10.33	113.50% Upside
PHAT Phathom Pharmaceuticals	2.88	Moderate Buy	$22.86	157.69% Upside

Current Analyst Ratings Breakdown

Latest NERV, HELP, ACHV, and PHAT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/20/2026	HELP Cybin	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$8.00 ➝ $62.00
8/19/2026	ACHV Achieve Life Sciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/14/2026	PHAT Phathom Pharmaceuticals	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$18.00 ➝ $14.00
8/14/2026	NERV Minerva Neurosciences	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Mixed	$7.50 ➝ $10.00
8/13/2026	ACHV Achieve Life Sciences	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$13.00
8/12/2026	ACHV Achieve Life Sciences	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Strong-Buy	$18.00
8/12/2026	ACHV Achieve Life Sciences	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/12/2026	ACHV Achieve Life Sciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$12.00
8/12/2026	NERV Minerva Neurosciences	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
7/31/2026	PHAT Phathom Pharmaceuticals	Craig Hallum Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$20.00
7/31/2026	PHAT Phathom Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$25.00 ➝ $22.00

(Data available from 8/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACHV Achieve Life Sciences	N/A	N/A	N/A	N/A	$0.40 per share	N/A
HELP Cybin	N/A	N/A	N/A	N/A	$4.49 per share	N/A
NERV Minerva Neurosciences	N/A	N/A	N/A	N/A	($3.25) per share	N/A
PHAT Phathom Pharmaceuticals	$175.11M	4.10	N/A	N/A	($6.14) per share	-1.44

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACHV Achieve Life Sciences	-$54.65M	-$1.55	N/A	N/A	N/A	N/A	-511.12%	-82.35%	11/5/2026 (Estimated)
HELP Cybin	-$148M	-$3.02	N/A	N/A	N/A	N/A	-71.78%	-64.81%	N/A
NERV Minerva Neurosciences	-$293.42M	-$28.87	N/A	N/A	N/A	N/A	N/A	-31.72%	11/4/2026 (Estimated)
PHAT Phathom Pharmaceuticals	-$221.25M	-$1.28	N/A	7.65	N/A	-41.34%	N/A	-20.81%	10/29/2026 (Estimated)

Latest NERV, HELP, ACHV, and PHAT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q1 2027	HELP Cybin	-$0.80	-$0.91	-$0.11	-$0.91	N/A	N/A
8/11/2026	Q2 2026	ACHV Achieve Life Sciences	-$0.1649	-$0.80	-$0.6351	-$0.80	N/A	N/A
8/7/2026	Q2 2026	NERV Minerva Neurosciences	-$0.1933	-$0.14	+$0.0533	-$0.14	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACHV Achieve Life Sciences	N/A	N/A	N/A	N/A	N/A
HELP Cybin	N/A	N/A	N/A	N/A	N/A
NERV Minerva Neurosciences	N/A	N/A	N/A	N/A	N/A
PHAT Phathom Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACHV Achieve Life Sciences	0.87	0.95	0.95
HELP Cybin	N/A	10.97	10.97
NERV Minerva Neurosciences	N/A	20.15	20.14
PHAT Phathom Pharmaceuticals	N/A	1.92	1.87

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACHV Achieve Life Sciences	33.52%
HELP Cybin	17.94%
NERV Minerva Neurosciences	34.56%
PHAT Phathom Pharmaceuticals	99.01%

Insider Ownership

Company	Insider Ownership
ACHV Achieve Life Sciences	1.80%
HELP Cybin	15.00%
NERV Minerva Neurosciences	1.70%
PHAT Phathom Pharmaceuticals	9.33%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACHV Achieve Life Sciences	20	102.90 million	101.05 million	Optionable
HELP Cybin	50	73.06 million	62.10 million	N/A
NERV Minerva Neurosciences	9	47.75 million	46.94 million	Not Optionable
PHAT Phathom Pharmaceuticals	110	80.90 million	73.35 million	Optionable

NERV, HELP, ACHV, and PHAT Headlines

Recent News About These Companies

Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Down 8.2% - What's Next?

August 20, 2026 | marketbeat.com

3,496,808 Shares in Phathom Pharmaceuticals, Inc. $PHAT Acquired by Carlyle Group Inc.

August 18, 2026 | marketbeat.com

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

August 17, 2026 | marketbeat.com

Phathom Pharmaceuticals’ Earnings Call Signals Profitable Growth

August 15, 2026 | tipranks.com

Hennion & Walsh Asset Management Inc. Has $3.55 Million Stake in Phathom Pharmaceuticals, Inc. $PHAT

August 11, 2026 | marketbeat.com

Renaissance Technologies LLC Acquires New Holdings in Phathom Pharmaceuticals, Inc. $PHAT

August 9, 2026 | marketbeat.com

Phathom Pharmaceuticals (NASDAQ:PHAT) Trading Down 5.5% - Here's Why

August 4, 2026 | marketbeat.com

Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Phathom Pharmaceuticals, Inc. (PHAT)

August 4, 2026 | globenewswire.com

PHAT Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Phathom Pharmaceuticals, Inc. (PHAT)

August 3, 2026 | businesswire.com

925,000 Shares in Phathom Pharmaceuticals, Inc. $PHAT Purchased by Perceptive Advisors LLC

August 2, 2026 | marketbeat.com

Phathom Pharmaceuticals, Inc. 2026 Q2 - Results - Earnings Call Presentation

August 1, 2026 | seekingalpha.com

Phathom forecasts $310M-$325M 2026 revenue while planning Phase 3 as-needed GERD trial in Q4

August 1, 2026 | seekingalpha.com

PHAT stock clocks worst day in over 1.5 years — what sparked the selloff?

July 30, 2026 | msn.com

Phathom Pharmaceuticals, Inc. (PHAT) Q2 2026 Earnings Call Transcript

July 30, 2026 | seekingalpha.com

Phathom Pharmaceuticals (PHAT) Q2 2026 Earnings

July 30, 2026 | 247wallst.com

Phathom Pharmaceuticals (NASDAQ:PHAT) Releases Earnings Results, Misses Expectations By $0.02 EPS

July 30, 2026 | marketbeat.com

Phathom Pharmaceuticals Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Phathom Pharmaceuticals (PHAT)

July 30, 2026 | prnewswire.com

Needham & Company LLC Has Lowered Expectations for Phathom Pharmaceuticals (NASDAQ:PHAT) Stock Price

July 30, 2026 | marketbeat.com

Phathom Pharmaceuticals Q2 Earnings Call Highlights

July 30, 2026 | marketbeat.com

Phathom Pharmaceuticals, Inc. (PHAT) Reports Break-Even Earnings for Q2

July 30, 2026 | zacks.com

Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Gap Down on Disappointing Earnings

July 30, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NERV, HELP, ACHV, and PHAT Company Descriptions

Achieve Life Sciences NASDAQ:ACHV

$7.99 0.00 (0.00%)

As of 08/21/2026 04:00 PM Eastern

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol Achieve Life Sciences, Inc. is based in Vancouver, Canada.

Cybin NASDAQ:HELP

$12.59 0.00 (0.00%)

As of 08/21/2026 04:00 PM Eastern

Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a discovery-phase phenethylamine derivative to treat neuroinflammation and psychiatric conditions. It has also developed EMBARK, a psychedelic-assisted psychotherapy. The company is headquartered in Toronto, Canada.

Minerva Neurosciences NASDAQ:NERV

$4.84 0.00 (0.00%)

As of 08/21/2026 04:00 PM Eastern

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.

Phathom Pharmaceuticals NASDAQ:PHAT

$8.87 0.00 (0.00%)

As of 08/21/2026 04:00 PM Eastern

Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NERV, HELP, ACHV, and PHAT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NERV, HELP, ACHV, and PHAT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NERV, HELP, ACHV, and PHAT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

NERV, HELP, ACHV, and PHAT Company Descriptions

Achieve Life Sciences NASDAQ:ACHV

Cybin NASDAQ:HELP

Minerva Neurosciences NASDAQ:NERV

Phathom Pharmaceuticals NASDAQ:PHAT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NERV, HELP, ACHV, and PHAT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NERV, HELP, ACHV, and PHAT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NERV, HELP, ACHV, and PHAT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

NERV, HELP, ACHV, and PHAT Company Descriptions

Achieve Life Sciences NASDAQ:ACHV

Cybin NASDAQ:HELP

Minerva Neurosciences NASDAQ:NERV

Phathom Pharmaceuticals NASDAQ:PHAT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools